Latest news
How Q2 Results and Alina GLP-1 Approvals At Stevanato Group (STVN) Have Changed Its Investment Story - simplywall.stsimplywall.st · Sun, 09 Aug 2026 08:50:33 GMTStevanato Group Q2 Earnings Call Highlights - MarketBeatMarketBeat · Sun, 09 Aug 2026 08:09:41 GMTLiraglutide combination products using Stevanato Group pen gain European approval - Drug Store NewsDrug Store News · Fri, 07 Aug 2026 12:30:51 GMTStevanato Group Q2 2026 Earnings Call Highlights - TipRanksTipRanks · Wed, 05 Aug 2026 05:16:22 GMTStevanato Group (NYSE:STVN) Releases Earnings Results, Beats Expectations By $0.01 EPS - MarketBeatMarketBeat · Tue, 04 Aug 2026 15:26:18 GMTSTVN: Q2 2026 delivered robust revenue and margin growth, led by high-value biologics and GLP-1 solutions - TradingViewTradingView · Tue, 04 Aug 2026 14:50:29 GMTStevanato Group (STVN) Could Be 19% Undervalued As Alina Pen Approvals Expand In Europe - SahmSahm · Sat, 01 Aug 2026 07:00:00 GMTPen Injector Received Marketing Authorizations in Multiple European Countries - Business WireBusiness Wire · Thu, 30 Jul 2026 10:30:00 GMT